CardioMEMS was founded in 2000 in order to pursue commercial applications of micro-electromechanical systems (MEMS) developed in the laboratories of Georgia Tech and M.I.T. for use in patients with a variety of disorders including abdominal aortic aneurysms (AAA) and congestive heart failure (CHF). The CardioMEMS AAA Pressure Sensor, an implantable MEMS-based device designed to monitor pressure in the space between an endovascular graft and the arterial wall, entered its first phase of human trials in early 2003. The initiation of clinical trials for the CardioMEMS Heart Pressure Sensor, a similar product designed for surgical insertion into the left ventricle of heart failure patients, occurred shortly thereafter achieving 510k approval and obtaining the CE mark for its AAA product. A larger market opportunity is available for the company’s CHF sensor, for which the company recently received regulatory approval. In May 2014 St. Jude Medical (NYSE: STJ) acquired CardioMEMS in an all cash transaction valued at $463 million.

Related News
Boston Millennia Partners Portfolio Company, CardioMEMS HF System Tests Positive
St. Jude Medical’s evaluation of the CardioMEMS Heart Failure (HF) System shows a significant reduction in 30-day hospital readmission rates for patients aged 65 and above. The System is a first-of-its-kind monitoring device that tracks the level of pressure borne by heart-failure patients. Read Full Release
Boston Millennia Partners Portfolio Company, CardioMEMS, Featured on CBS Evening News
A CBS News Boston special report features Millennia Portfolio Company, CardioMEMS', heart failure monitor in use at Brigham and Women's Hospital. Read Full Release
Dana Callow Featured on MassDevice
Managing Partner, Dana Callow, discusses the sale of portfolio company CardioMEMS to St. Jude Medical with MassDevice. Read Full Release
Boston Millennia Partners announces the sale of its portfolio company CardioMEMS to St. Jude Medical
Boston Millennia Partners is pleased to announce that St. Jude Medical (NYSE: STJ) has acquired the remaining 81 percent of CardioMEMS, Inc. it does not own for $375 million dollars. Read Full Release
St. Jude Medical and CardioMEMS Announce FDA Approval of the CardioMEMS Heart Failure Management System
ST. PAUL, Minn. & ATLANTA--(BUSINESS WIRE)-- St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, and CardioMEMS, today announced U.S. Food and Drug Administration (FDA) approval of the CardioMEMS™ HF System. The CardioMEMS HF System is the first and only FDA-approved heart failure (HF) monitoring device that has been proven to significantly reduce HF hospital admissions when used by physicians to manage heart failure. Read Full Release